[1] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] XIA C,DONG X,LI H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants[J].Chin Med J (Engl),2022,135(5):584-590.
[3] WHARTON S,LAU DCW,VALLIS M,et al.Obesity in adults:a clinical practice guideline[J].CMAJ,2020,192(31):E875-E891.
[4] PAN XF,WANG L,PAN A.Epidemiology and determinants of obesity in China[J].Lancet Diabetes Endocrinol,2021,9(6):373-392.
[5] MIETHE S,KARSONOVA A,KARAULOA A,et al.Obesity and asthma[J].J Allergy Clin Immunol,2020,146(4):685-693.
[6] LI J,ZHU L,WEI Y,et al.Association between adiposity measures and COPD risk in Chinese adults[J].Eur Respir J,2020,55(4):1901899.
[7] MAIR KM,HARVEY KY,HENRY AD,et al.Obesity alters oestrogen metabolism and contributes to pulmonary arterial hypertension[J].Eur Respir J,2019,53(6):1801524.
[8] HONORE PM,GUTIERREZ LB,REDANT S,et al.Obesity ipopulation!nducing acute respiratory distress syndrome:we should choose the right[J].Crit Care,2019,23(1):328.
[9] ZHOU W,LIU G,HUNG RJ,et al.Causal relationships between body mass index,smoking and lung cancer:Univariable and multivariable Mendelian randomization[J].Int J Cancer,2021,148(5):1077-1086.
[10] PETRELLI F,CORTELLINI A,INDINI A,et al.Association of obesity with survival outcomes in patients with cancer:A systematic review and Meta-analysis[J].JAMA Netw Open,2021,4(3):e213520.
[11] SHEPSHELOVICH D,XU W,LU L,et al.Body mass index (BMI),BMI change,and overall survival in patients with SCLC and NSCLC:A pooled analysis of the international lung cancer consortium[J].J Thorac Oncol,2019,14(9):1594-1607.
[12] YOU D,WANG D,WU Y,et al.Associations of genetic risk,BMI trajectories,and the risk of non-small cell lung cancer:a population-based cohort study[J].BMC Med,2022,20(1):203.
[13] FINGERET M,MARQUES-VIDAL P,VOLLENWEIDER P.Incidence of type 2 diabetes,hypertension,and dyslipidemia in metabolically healthy obese and non-obese[J].Nutr Metab Cardiovasc Dis,2018,28(10):1036-1044.
[14] XIAO K,LIU F,LIU J,et al.The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes mellitus:A meta-analysis[J].J Clin Pharm Ther,2020,45(4):783-792.
[15] BARRIOS-BERNAL P,ZATARAIN-BARRON ZL,HERNANDEZ-PEDRO N,et al.Will we unlock the benefit of metformin for patients with lung cancer?Lessons from current evidence and new hypotheses[J].Pharmaceuticals (Basel),2022,15(7):786.
[16] YENDAMUEI S,BARBI J,PABLA S,et al.Body mass index influences the salutary effects of metformin on survival after lobectomy for stage I NSCLC[J].J Thorac Oncol,2019,14(12):2181-2187.
[17] WANG Y,HU Y,WANG T,et al.Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents[J].Front Pharmacol,2023,14:1123834.
[18] AMIN F,FATHI F,REINER Z,et al.The role of statins in lung cancer[J].Arch Med Sci,2021,18(1):141-152.
[19] ZHOU Q,JIAO Z,LIU Y,et al.The effects of statins in patients with advanced-stage cancers-a systematic review and meta-analysis[J].Front Oncol,2023,13:1234713.
[20] DE PERGOLA G,GIAGULLI VA,GUASTAMACCHIA E,et al.Platelet number is positively and independently associated with glycated hemoglobin in non-diabetic overweight and obese subjects[J].Nutr Metab Cardiovasc Dis,2019,29(3):254-259.
[21] GRANDE R,DOVIZIO M,MARCONE S,et al.Platelet-derived microparticles from obese individuals:Characterization of number,size,proteomics,and crosstalk with cancer and endothelial cells[J].Front Pharmacol,2019,10:7.
[22] SIMEONE P,LIANI R,TRIPALDI R,et al.Thromboxane-dependent platelet activation in obese subjects with prediabetes or early type 2 diabetes:Effects of liraglutide- or lifestyle changes-induced weight loss[J].Nutrients,2018,10(12):1872.
[23] LICHTENBERGER LM,VIJAYAN KV.Are platelets the primary target of aspirin's remarkable anticancer activity[J].Cancer Res,2019,79(15):3820-3823.
[24] ZHU Y,WEI Y,ZHANG R,et al.Elevated platelet count appears to be causally associated with increased risk of lung cancer:A mendelian randomization analysis[J].Cancer Epidemiol Biomarkers Prev,2019,28(5):935-942.
[25] DONG X,HE J,LIN L,et al.Association between aspirin use and lung cancer incidence depends on high-frequency use,bodyweight,and age in U.S. adults[J]. Transl Lung Cancer Res,2021,10(1):392-401.
[26] YU SY,IP MS,LI X,et al.Low-dose aspirin and incidence of lung carcinoma in patients with chronic obstructive pulmonary disease in Hong Kong:A cohort study[J].PLoS Med,2022,19(1):e1003880.
[27]KANG J,JEONG SM,SHIN DW,et al.The associations of aspirin,statins,and metformin with lung cancer risk and related mortality:A time-dependent analysis of population-based nationally representative data[J].J Thorac Oncol,2021,16(1):76-88.
[28] WATANABE T,TSUJINO I,KONNO S,et al.Association between smoking status and obesity in a nationwide survey of Japanese adults[J].PLoS One,2016,11(3):e0148926.
[29] TAYLOR AE,RICHMOND RC,PALVIAINEN T,et al.The effect of body mass index on smoking behaviour and nicotine metabolism:a Mendelian randomization study[J].Hum Mol Genet,2019,28(8):1322-1330.
[30] YAMAZAKI A,KINOSE D,KAWASHIMA S,et al.Predictors of longitudinal changes in body weight,muscle and fat in patients with and ever-smokers at risk of COPD[J].Respirology,2023,28(9):851-859.
[31] 闫焱,焦碧航,周昆,等.基线BMI与免疫检查点抑制剂治疗晚期非小细胞肺癌疗效的关系[J].郑州大学学报(医学版),2023,58(03):373-377.
YAN Y,JIAO BH,ZHOU K,et al.Relationship between baseline body mass index and efficacy of immune checkpoint inhibitors in patients with advan ced non-small cell lung cancer [J].Journal of Zhengzhou University (Medical Edition),2023,58(03):373-377.
[32] OSTRAND-ROSENBERG S.Myeloid derived-suppressor cells:their role in cancer and obesity[J].Curr Opin Immunol,2018,51:68-75.
[33] ZENG Q,WANG L,DONG S,et al.CT-derived abdominal adiposity:Distributions and better predictive ability than BMI in a nationwide study of 59429 adults in China[J].Metabolism,2021,115:154456.
[34] DONINI LM,PINTO A,GIUSTI AM,et al.Obesity or BMI paradox?Beneath the tip of the iceberg[J].Front Nutr,2020,7:53.
[35] JEONG SM,LEE DH,GIOVANNUCCI EL.Predicted lean body mass,fat mass and risk of lung cancer:prospective US cohort study[J].Eur J Epidemiol,2019,34(12):1151-1160.
[36] OSWALT C,LIU Y,PANG H,et al.Associations between body mass index,weight loss and overall survival in patients with advanced lung cancer[J].J Cachexia Sarcopenia Muscle,2022,13(6):2650-2660.
[37] BARBERIO AM,ALAREEKIA,VINER B,et al.Central body fatness is a stronger predictor of cancer risk than overall body size[J].Nat Commun,2019,10(1):383.
[38] KOENEN M,HILL MA,COHEN P,et al.Obesity,adipose tissue and vascular dysfunction[J].Circ Res,2021,128(7):951-968.
[39] NEELAND IJ,ROSS R,DESPRES JP,et al.Visceral and ectopic fat,atherosclerosis,and cardiometabolic disease:a position statement[J].Lancet Diabetes Endocrinol,2019,7(9):715-725.
[40] 李岳航,王愿,李义帅,等.内脏脂肪在肺癌中的研究进展[J].实用医学杂志,2022,38(10):1292-1297.
LI YH,WANG Y,LI YS,et al.Research progress of visceral fat in lung cancer[J].Journal of Practical Medicine,2022,38(10):1292-1297.
[41] ARDESCH FH,RUITER R,MULDER M,et al.The obesity paradox in lung cancer:Associations with body size versus body shape[J].Front Oncol,2020,10:591110.
[42] YU D,ZHENG W,JOHANSSON M,et al.Overall and central obesity and risk of lung cancer:A pooled analysis[J].J Natl Cancer Inst,2018,110(8):831-842.
[43] BARBI J,PATNAIK SK,PABLA S,et al.Visceral obesity promotes lung cancer progression-toward resolution of the obesity paradox in lung cancer[J].J Thorac Oncol,2021,16(8):1333-1348.
[44] NITSCHE L,VEDIRE Y,KANNISTO E,et al.Visceral obesity in non-small cell lung cancer[J].Cancers (Basel),2022,14(14):3450.
[45] CHRISTAKOUDI S,TSILIDIS KK,MULLER DC,et al.A body shape index (ABSI) achieves better mortality risk stratification than alternative indices of abdominal obesity:results from a large European cohort[J].Sci Rep,2020,10(1):14541.